Related Experiment Videos
Matrix metalloproteinases and processing of pro-TNF-alpha
A J Gearing1, P Beckett, M Christodoulou
1Neures Ltd., Abingdon, Oxon, UK.
Journal of Leukocyte Biology
|May 1, 1995
Summary
Matrix metalloproteinases (MMPs) are crucial for releasing tumor necrosis factor-alpha (TNF-alpha). MMP inhibitors effectively block TNF-alpha release and show promise for treating inflammatory diseases.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory cytokine.
- TNF-alpha is produced from a membrane-bound precursor via proteolytic cleavage.
- Matrix metalloproteinases (MMPs) are implicated in this processing.
Purpose of the Study:
- To investigate the role of MMPs in TNF-alpha precursor processing.
- To evaluate the efficacy of MMP inhibitors in controlling TNF-alpha release and inflammatory conditions.
Main Methods:
- Utilized broad-spectrum synthetic MMP inhibitors.
- Tested purified MMPs (stromelysin, matrilysin, collagenase, gelatinases) on recombinant pro-TNF.
- Administered MMP inhibitors to rats challenged with endotoxin.
- Assessed MMP inhibitor efficacy in adjuvant arthritis models.
Main Results:
- Broad-spectrum MMP inhibitors prevented TNF-alpha precursor processing without affecting other cytokine release.
- Purified MMPs demonstrated the ability to cleave pro-TNF into mature TNF.
- MMP inhibitors successfully inhibited the rise in blood TNF levels post-endotoxin administration in rats.
- MMP inhibitors proved effective in animal models of inflammatory disease, including adjuvant arthritis.
Conclusions:
- MMPs are key enzymes responsible for the proteolytic cleavage of the TNF-alpha precursor.
- MMP inhibitors effectively block TNF-alpha release.
- Inhibiting MMPs and subsequent TNF-alpha release represents a promising therapeutic strategy for autoimmune inflammatory diseases.